单次与分次术前放射外科治疗切除脑转移瘤:PROPS-BM国际多中心队列研究
该国际多中心队列研究纳入8家机构的404例脑转移瘤患者(416个可切除病灶),比较术前单次放射外科(SF-SRS,317例)与分次(3-5次)放射外科(MF-SRS,87例)的结局与毒性。结果显示MF-SRS与显著降低的瘤腔局部复发相关(未匹配2年16.3% vs 2.9%,P=.004;倾向评分匹配2年19.8% vs 3.3%,P=.003),不良放射效应、脑膜病变和总生存无差异。作者认为MF-SRS可能为切除脑转移瘤新辅助放疗的优先选择,需进一步验证研究。
要点
- 术前分次SRS较单次SRS与显著降低的瘤腔局部复发相关(匹配后2年3.3% vs 19.8%,P=.003)。
- 两组不良放射效应、脑膜病变和总生存无显著差异。
- 作者认为MF-SRS可能为切除脑转移瘤新辅助放疗的优先选择,需进一步验证。
核心结论
- 术前MF-SRS在未匹配和倾向评分匹配分析中均与显著降低的瘤腔局部复发风险相关。
- 分次方案与单次方案在不良放射效应、脑膜病变或总生存方面无差异。
- 作者认为MF-SRS可能为切除脑转移瘤新辅助放疗的优先选择,需额外验证研究。
研究设计与样本
- 国际多中心队列研究(PROPS-BM),纳入8家机构中至少1个病灶接受术前SRS后计划切除的实体瘤脑转移患者。
- 共纳入404例患者、416个切除指数病灶;SF-SRS用于317例(78.5%),MF-SRS用于87例(21.5%)。
- 允许对同步未切除脑转移灶行SRS;排除既往或计划全脑放疗者;采用竞争风险累积发生率估计颅内结局,并进行倾向评分匹配(PSM)分析。
主要发现
- SF-SRS中位剂量为15 Gy单次;MF-SRS中位剂量为24 Gy分3次。
- 未匹配分析中,SF-SRS较MF-SRS与更高的瘤腔局部复发相关(2年:16.3% vs 2.9%;P=.004),多因素分析亦显示该关联。
- PSM产生81对匹配(n=162);PSM分析同样显示SF-SRS的瘤腔局部复发率显著更高(2年:19.8% vs 3.3%;P=.003)。
- 两种分析中,不良放射效应、脑膜病变或总生存 between 队列均无差异。
关键数值与推荐
- SF-SRS中位剂量15 Gy单次;MF-SRS中位剂量24 Gy分3次。
- 未匹配分析瘤腔局部复发2年:SF-SRS 16.3% vs MF-SRS 2.9%(P=.004)。
- PSM分析瘤腔局部复发2年:SF-SRS 19.8% vs MF-SRS 3.3%(P=.003)。
临床怎么用
- 作者认为MF-SRS可能为切除脑转移瘤新辅助放疗的优先选择。
- 作者指出需额外验证研究;单次术前与术后SRS的3期随机试验(NRG-BN012,NCT05438212)正在进行中。
局限性
- 作者指出需额外验证研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Preoperative stereotactic radiosurgery (SRS) is a feasible alternative to postoperative SRS for resected brain metastases (BM). Most reported studies of preoperative SRS used single-fraction SRS (SF-SRS). The goal of this study was to compare outcomes and toxicity of preoperative SF-SRS with multifraction (3-5 fractions) SRS (MF-SRS) in a large international multicenter cohort (Preoperative Radiosurgery for Brain Metastases-PROPS-BM). METHODS AND MATERIALS: Patients with BM from solid cancers, of which at least 1 lesion was treated with preoperative SRS followed by planned resection, were included from 8 institutions. SRS to synchronous intact BM was allowed. Exclusion criteria included prior or planned whole brain radiation therapy. Intracranial outcomes were estimated using cumulative incidence with competing risk of death. Propensity score matched (PSM) analyses were performed. RESULTS: The study cohort included 404 patients with 416 resected index lesions, of which SF-SRS and MF-SRS were used for 317 (78.5%) and 87 patients (21.5%), respectively. Median dose was 15 Gy in 1 fraction for SF-SRS and 24 Gy in 3 fractions for MF-SRS. Univariable analysis demonstrated that SF-SRS was associated with higher cavity local recurrence (LR) compared with MF-SRS (2-year: 16.3% vs 2.9%; P = .004), which was also demonstrated in multivariable analysis. PSM yielded 81 matched pairs (n = 162). PSM analysis also demonstrated significantly higher rate of cavity LR with SF-SRS (2-year: 19.8% vs 3.3%; P = .003). There was no difference in adverse radiation effect, meningeal disease, or overall survival between cohorts in either analysis. CONCLUSIONS: Preoperative MF-SRS was associated with significantly reduced risk of cavity LR in both the unmatched and PSM analyses. There was no difference in adverse radiation effect, meningeal disease, or overall survival based on fractionation. MF-SRS may be a preferred option for neoadjuvant radiation therapy of resected BMs. Additional confirmatory studies are needed. A phase 3 randomized trial of single-fraction preoperative versus postoperative SRS (NRG-BN012) is ongoing (NCT05438212).
引用
- Prabhu RS, Akinyelu T, Vaslow ZK, et al. Single-Fraction Versus Fractionated Preoperative Radiosurgery for Resected Brain Metastases: A PROPS-BM International Multicenter Cohort Study. Int J Radiat Oncol Biol Phys. 2023. PMID: 37717787. doi:10.1016/j.ijrobp.2023.09.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。